Palvella moves listing to Nasdaq Global Market

Palvella Therapeutics, Inc. has received approval from the Nasdaq Listing Qualifications Department to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market.

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. has received approval from the Nasdaq Listing Qualifications Department to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market. The change will be effective with the open of business on May 13, 2026.

The company’s common stock will continue to trade under the ticker symbol “PVLA”, and no change to the symbol accompanies this exchange tier transfer.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Nasdaq approval date: May 11, 2026 Effective transfer date: May 13, 2026

2 metrics

Nasdaq approval date May 11, 2026 Date Nasdaq Listing Qualifications Department approved transfer

Effective transfer date May 13, 2026 Date listing moves to Nasdaq Global Market

Key Terms

Nasdaq Capital Market, Nasdaq Global Market, Nasdaq Listing Qualifications Department, Emerging growth company, +1 more

5 terms

Nasdaq Capital Market financial

"to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Nasdaq Global Market financial

"to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

Nasdaq Listing Qualifications Department regulatory

"received approval from the Nasdaq Listing Qualifications Department to move the listing"

The Nasdaq Listing Qualifications Department is the team at the Nasdaq stock market that monitors whether listed companies meet the exchange’s rules for things like minimum share price, market value, timely financial reporting and governance. Its role matters to investors because its notices, warnings or enforcement actions—ranging from reminders to suspension or delisting—can sharply affect a stock’s trading, liquidity and perceived risk; think of it as the referee enforcing the marketplace’s entry and conduct rules.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Item 8.01 Other Events regulatory

"Item 8.01 Other Events. On May 11, 2026, Palvella Therapeutics, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) announce in this 8-K filing?

Palvella Therapeutics announced it received approval to move its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026, while continuing to use the ticker symbol PVLA.

When will Palvella Therapeutics’ PVLA shares begin trading on the Nasdaq Global Market?

Palvella Therapeutics’ PVLA shares will begin trading on the Nasdaq Global Market with the open of business on May 13, 2026. Before this date, the shares were listed on the Nasdaq Capital Market under the same ticker symbol.

Does Palvella Therapeutics change its ticker symbol with the Nasdaq Global Market move?

No, Palvella Therapeutics does not change its ticker symbol. The company states that its existing ticker symbol, PVLA, will remain the same after the transfer from the Nasdaq Capital Market to the Nasdaq Global Market.

Who approved Palvella Therapeutics’ transfer to the Nasdaq Global Market?

The Nasdaq Listing Qualifications Department approved Palvella Therapeutics’ transfer of its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, as stated in the company’s 8-K under Item 8.01 Other Events.

On what date did Palvella Therapeutics receive Nasdaq approval for the listing transfer?

Palvella Therapeutics received Nasdaq approval for the listing transfer on May 11, 2026. The company notes that this approval permits its common stock to move from the Nasdaq Capital Market to the Nasdaq Global Market, effective May 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 07:30 AM EDT Learn about SEC filing dates

false000158364800015836482026-05-112026-05-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2026

Palvella Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			001-37471	30-0784346
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
353 W. Lancaster Ave, Suite 200
Wayne, Pennsylvania				19087
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On May 11, 2026, Palvella Therapeutics, Inc. (the “Company”) received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026. The Company’s existing ticker symbol, “PVLA,” will not be affected by such exchange tier transfer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Palvella Therapeutics, Inc.
Date:	May 13, 2026	By:	/s/ Matthew Korenberg
			Matthew Korenberg
			Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB